Catheter Precision Showcasing its Innovative 3D Mapping System

Rhea-AI Summary

VIVO to be highlighted at electrophysiology conferences

Positive

• VIVO's 3D Mapping system received commendable feedback at recent conference
• Catheter Precision strengthens foothold in Italy with partnership with Precise S.r.l.
• Catheter Precision will also highlight their newly introduced product, LockeT, at conferences

Negative

• None.

VIVO to Be Highlighted at Several Electrophysiology Conferences

FORT MILL, SC / ACCESSWIRE / October 10, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK) announced that its innovative 3D Mapping system will be highlighted at several electrophysiology conferences this fall.

Most recently, VIVO was highlighted at the 19th Congresso Nazionale Associazione Italiana di Aritmologia e Cardiostimolazione in Bologna, Italy from September 21-22. Interim CEO David Jenkins remarked, "Our attendance not only highlighted our state-of-the-art technology but also cemented collaborations for evaluations at prominent VIVO sites, including Ospedale Della Misericordia Grosseto and Pisa CNR. VIVO received commendable feedback, recognizing its potential to revolutionize patient experience and EP lab efficiency."

Strengthening their foothold in Italy, Catheter Precision has strategically partnered with Precise S.r.l. "Our alliance with Precise S.r.l. is instrumental in solidifying our presence in the Italian medical landscape," Jenkins concluded.

In addition to VIVO, Catheter Precision will be present at other conferences also highlighting their newly introduced product, LockeT, a venous stasis closure device.

Future conferences that will highlight VIVO in the coming weeks are listed below.

• Irish Cardiac Society's 74^th Annual Scietific Meeting, October 12-14, 2023:
  • Presentation: "Testing the Validity of VIVO Technology: A Deep Dive into Ventricular Onset Mapping" by Professor Szeplaki's team from Mater Private Hospital, Dublin.
• 18^th Annual International Symposium on Ventricular Arrythmias, October 13-14, 2023
  • Location: Philadelphia, Pennsylvania
  • Spotlight: VIVO and LockeT products
• 7^th Annual Society of Cardiac RN Meeting, October 19-20, 2023:
  • Location: Washington, DC
  • Presentation: "3D Mapping for Robotic Ventricular Ablations Using VIVO" by Dr. Benjamin D'Souza from Penn Presbyterian Medical Center, Philadelphia, PA.

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About LockeT

Catheter Precision's LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Reincorporated as Ra Medical Systems, Inc. in Delaware in 2018, the Company changed its name to Catheter Precision, Inc. on August 17, 2023.

Forward Looking Statements

This communication contains forward-looking statements. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, our anticipated revenues during the second half of 2023, and the anticipated accounting for the merger with Catheter Precision. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov. These risks and uncertainties include, but aren't limited to, that we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, if our internal controls are not effective, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results. In addition, our auditor's finalization of the accounting for the merger requires complex calculations and the input of outside advisors, and as a result, the final results of these calculations could differ from our current expectations. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, supply chain disruptions from the Ukraine war and otherwise, and ongoing volatility in the stock markets and the U.S. economy in general.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

At the Company
Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

SOURCE: Catheter Precision, Inc

View source version on accesswire.com:
https://www.accesswire.com/791410/catheter-precision-showcasing-its-innovative-3d-mapping-system

FAQ

What is VIVO?

VIVO is an innovative 3D Mapping system by Catheter Precision, Inc.

What was the feedback on VIVO at the recent conference?

VIVO received commendable feedback, recognizing its potential to revolutionize patient experience and EP lab efficiency.

What is the partnership with Precise S.r.l. about?

The partnership with Precise S.r.l. is instrumental in solidifying Catheter Precision's presence in the Italian medical landscape.

What other product will Catheter Precision highlight at the conferences?

Catheter Precision will also highlight their newly introduced product, LockeT, a venous stasis closure device.

What are the upcoming conferences that will highlight VIVO?

The upcoming conferences that will highlight VIVO are the Irish Cardiac Society's 74th Annual Scientific Meeting, the 18th Annual International Symposium on Ventricular Arrhythmias, and the 7th Annual Society of Cardiac RN Meeting.